[Form 4] Pacific Biosciences of California, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Mark Van Oene, Chief Operating Officer of Pacific Biosciences of California, Inc. (PACB), reported a routine sale of shares to cover tax withholding upon RSU vesting. The Form 4 discloses that on 08/18/2025 he disposed of 26,836 shares at a weighted average sale price of $1.311 per share (sale prices ranged from $1.30 to $1.32). After the transaction he beneficially owns 1,920,035 shares. The filing explains the shares were automatically sold to satisfy tax withholding obligations related to restricted stock unit vesting. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine RSU tax-withholding sale by an executive, leaving substantial retained ownership; not a governance-red flag.
The disclosure indicates an automatic sale of 26,836 shares to satisfy tax obligations arising from RSU vesting, a common administrative practice. Retaining 1,920,035 shares suggests continued alignment with shareholders. There are no indications of opportunistic trading or a larger divestiture. The filing is complete with a weighted average sale price and range provided as required.
TL;DR: Small, routine insider sale; minimal market impact given size relative to total reported holdings.
The transaction was coded as a sale to cover tax withholding, with 26,836 shares sold at a weighted average price of $1.311 (range $1.30–$1.32). The post-transaction beneficial ownership of 1,920,035 shares is explicitly stated. No derivative transactions or other dispositions are reported. This Form 4 provides the standard disclosures expected for RSU vesting-related sales.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 26,836 | $1.311 | $35K |
Footnotes (1)
- Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale price represents the weighted average sale price of the shares sold ranging from $1.30 to $1.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.